From: Computational methods and resources for the interpretation of genomic variants in cancer
Cancer Type | Donors | Total Unique Mutations | Total Recurrent Mutations | Donors with Recurrent Mutations |
---|---|---|---|---|
BLCA | 233 | 53,638 | 737 (1.4%) | 219 (94.0%) |
BOCA | 66 | 1,422 | 7 (0.5%) | 39 (59.1%) |
BRCA | 1,071 | 275,612 | 1,252 (0.5%) | 929 (86.7%) |
CLLE | 109 | 5,292 | 4 (0.1%) | 10 (9.2%) |
CMDI | 129 | 86 | 13 (15.1%) | 113 (87.6%) |
COAD | 216 | 105,786 | 3,896 (3.7%) | 215 (99.5%) |
EOPC | 11 | 25,575 | 2 (0.0%) | 4 (36.4%) |
ESAD | 95 | 1,780,883 | 25,425 (1.4%) | 95 (100.0%) |
ESCA | 88 | 7,256 | 17 (0.2%) | 37 (42.0%) |
GACA | 9 | 1,014 | 0 (0.0%) | 0 (0.0%) |
GBM | 268 | 19,852 | 324 (1.6%) | 260 (97.0%) |
KIRC | 404 | 26,371 | 688 (2.6%) | 372 (92.1%) |
KIRP | 156 | 12,932 | 218 (1.7%) | 144 (92.3%) |
LAML | 75 | 60,203 | 7,623 (12.7%) | 71 (94.7%) |
LGG | 279 | 13,083 | 432 (3.3%) | 278 (99.6%) |
LIAD | 30 | 917 | 11 (1.2%) | 19 (63.3%) |
LICA | 29 | 747,334 | 27,107 (3.6%) | 6 (20.7%) |
LINC | 244 | 437,403 | 6003 (1.4%) | 244 (100.0%) |
LIRI | 208 | 2,124,689 | 4161 (0.2%) | 208 (100.0%) |
LUSC | 289 | 125,351 | 1400 (1.1%) | 268 (92.7%) |
MALY | 44 | 311,297 | 686 (0.2%) | 44 (100.0%) |
NBL | 41 | 137 | 2 (1.5%) | 4 (9.8%) |
ORCA | 50 | 5,604 | 35 (0.6%) | 38 (76.0%) |
OV | 181 | 919,769 | 869 (0.1%) | 119 (65.7%) |
PACA | 504 | 1,630,944 | 6,098 (0.4%) | 500 (96.5%) |
PAEN | 35 | 112,823 | 804 (0.7%) | 32 (91.4%) |
PBCA | 248 | 130,608 | 1,231 (0.9%) | 89 (35.9%) |
PRAD | 264 | 90,599 | 776 (0.9%) | 256 (96.7%) |
READ | 80 | 23,499 | 556 (2.4%) | 80 (100.0%) |
RECA | 105 | 475,986 | 6,067 (1.3%) | 95 (90.5%) |
SKCM | 323 | 226,850 | 11,908 (5.2%) | 323 (100.0%) |
STAD | 289 | 142,496 | 3,441 (2.4%) | 276 (95.5%) |
THCA | 411 | 51,759 | 4,619 (8.9%) | 311 (75.7%) |
PanCancer | 6,584 | 9,871,474 | 171,314 (1.7%) | 6,296 (95.6%) |